105-LB: Real-World Outcomes of Addition of Insulin Glargine 300 U/mL (Gla-300) to GLP-1RA Therapy in People with Type 2 Diabetes (PWD2): The DELIVER-G Study

Abstract

In PWD2 inadequately controlled with GLP-1 RA therapy, addition of basal insulin is recommended. We used a US electronic medical record data source (IBM Explorys) of ~4 million PWD2 to assess the real-world impact of adding the basal insulin analog Gla-300 to GLP-1RA therapy in PWD2. Insulin-naive PWD2 receiving GLP1-RAs who subsequently received Gla-300 between Mar 1, 2015-Sep 30, 2019 were identified; patients were required to have data for ≥12 months prior, and ≥6-month after, addition of Gla-300. Mean age of participants (N=271) was 57.9 (SD: 10.8) years. Baseline HbA1c was 9.16%, and was significantly reduced (0.97 [SD:1.60], p Disclosure T. S. Bailey: Consultant; Self; Abbott Diabetes, LifeScan, Novo Nordisk, Sanofi, Research Support; Self; Abbott, Abbott Diabetes, Biolinq, Capillary Biomedical, Inc., Dexcom, Inc., Eli Lilly and Company, Kowa Research Institute, Inc., Lexicon Pharmaceuticals, Inc., Livongo, Medtronic, Medtrum Technologies, Novo Nordisk, REMD Biotherapeutics, Sanofi, Sanvita, Viacyte, Inc., vTv Therapeutics, Zealand Pharma A/S, Speaker’s Bureau; Self; BD, Medtronic, Sanofi. J. Westerbacka: Employee; Self; Sanofi, Stock/Shareholder; Self; Sanofi. C. Nicholls: Employee; Self; Sanofi. J. Gill: Employee; Self; Sanofi US, Other Relationship; Self; American Diabetes Association, Stock/Shareholder; Self; Sanofi US. M. Jones s: None. L. Shenoy: None. Funding Sanofi